Eligible patients with stage IV or unresectable stage IIIC melanoma selected to undergo either anti-CTLA-4 antibody (ipilimumab) or anti-PD-1 antibody (pembrolizumab, nivolumab) immunotherapy will be asked to participate in the study by the Principal Investigator, co-Investigators, or clinical staff.